SCHEMBL3058692

SCHEMBL3058692

O=S(=O)(O)c1ccc2[nH]ncc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.55
NOS1 P29475 4/20 0.51
MAPT P10636 2/20 0.51
POLB P06746 1/20 0.51
MAOB P27338 1/20 0.51
ROCK2 O75116 5/20 0.51
ROCK1 Q13464 5/20 0.51
RAB9A P51151 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
METAP2 P50579 1/20 0.50
CSNK2A1 P68400 1/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.50
HIF1A Q16665 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ACLY P53396 1/20 0.47
NPC1 O15118 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27659736 0.98 MAPK1 (0.54) MAPK1NOS1MAPTPOLBMAOB
SCHEMBL31475220 0.86 NOS1 (0.51) MAPK1NOS1MAPTMEN1KMT2A
SCHEMBL4654871 0.86 NOS1 (0.51) MAPK1NOS1MAPTMEN1KMT2A
SCHEMBL6298004 0.82 NOS1 (0.51) MAPK1NOS1MAPTPOLBMAOB
SCHEMBL29509879 0.82 NOS1 (0.55) MAPK1NOS1MAPTPOLBMAOB
SCHEMBL5220947 0.82 KDR (0.57) MAPK1NOS1MAPTPOLBMAOB
SCHEMBL692845 0.82 NOS1 (0.55) MAPK1NOS1MAPTPOLBMAOB
SCHEMBL31647068 0.82 KDR (0.57) MAPK1NOS1MAPTPOLBMAOB
SCHEMBL10179696 0.82 TMEM97 (0.52) MAPK1NOS1MAPTPOLBMAOB
SCHEMBL19639914 0.78 ROCK2 (0.50) MAPK1NOS1MAPTPOLBMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114773266-B Improved synthesis method of montelukast sodium 牡丹江恒远药业股份有限公司 2022-12-27 CN claimed
CN-114773266-A Improved synthesis method of montelukast sodium 牡丹江恒远药业股份有限公司 2022-07-22 CN claimed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 US claimed
CN-114773266-B Improved synthesis method of montelukast sodium 牡丹江恒远药业股份有限公司 2022-12-27 CN disclosed
CN-114773266-A Improved synthesis method of montelukast sodium 牡丹江恒远药业股份有限公司 2022-07-22 CN disclosed
US-10752617-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-08-25 US disclosed
US-20190202819-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-07-04 US disclosed
US-10246440-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-04-02 US disclosed
US-20170342062-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-11-30 US disclosed
EP-2610247-B1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LTD (BS) 2016-05-25 EP disclosed
EP-2265589-B1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LTD (BS) 2016-01-27 EP disclosed
EP-0696759-B1 Method for processing a silver halide photographic light-sensitive material KONISHIROKU PHOTO IND (JP) 2000-03-29 EP disclosed
US-5707788-A REDUCING DEVELOPER WASTE WHILE MAINTAINING IMAGE QUALITY, BLACK AND WHITE KONICA CORPORATION (JP) 1998-01-13 US disclosed
EP-0554000-B1 A black-and-white silver halide photographic light-sensitive material and a method for processing the same KONISHIROKU PHOTO IND (JP) 1997-03-19 EP disclosed
EP-0696759-A2 Method for processing a silver halide photographic light-sensitive material KONICA CORPORATION (JP) 1996-02-14 EP disclosed
US-5376509-A Comprising cyclodextrin compounds and devloper; storage stable KONICA CORPORATION (JP) 1994-12-27 US disclosed
US-5352563-A At least one of emulsion and protective layers contains a cyclodextrin compound; hydrazine derivative or tetrazolium salt in emulsion layer KONICA CORPORATION (JP) 1994-10-04 US disclosed
EP-0554000-A1 A black-and-white silver halide photographic light-sensitive material and a method for processing the same KONICA CORPORATION (JP) 1993-08-04 EP disclosed
EP-0545645-A1 Solid processing chemicals for light-sensitive halide photographic material KONICA CORPORATION (JP) 1993-06-09 EP disclosed
EP-0358165-A2 Method of developing a silver halide photographic material KONICA CORPORATION (JP) 1990-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246440-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) RORA, RORB, RORC MAPK1 3487/4885NOS1 2823/4885MAPT 673/4885
US-20170342062-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC MAPK1 3509/4885NOS1 2915/4885MAPT 664/4885
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, TYK2 MAPK1 386/4885NOS1 1181/4885MAPT 3747/4885
US-20190202819-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC MAPK1 3509/4885NOS1 2915/4885MAPT 664/4885
US-10752617-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) RORA, RORB, RORC MAPK1 3509/4885NOS1 2915/4885MAPT 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.